Cargando…
Immune Checkpoint Inhibition in Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma (HNSCC) is the 6th most common cancer globally and commonly presents with locally advanced disease, which has a recurrence rate of around 50% despite aggressive multi-modality treatment involving surgery, radiotherapy and chemotherapy or EGFR inhibition where ap...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6123367/ https://www.ncbi.nlm.nih.gov/pubmed/30211111 http://dx.doi.org/10.3389/fonc.2018.00310 |
_version_ | 1783352824584732672 |
---|---|
author | Forster, Martin David Devlin, Michael-John |
author_facet | Forster, Martin David Devlin, Michael-John |
author_sort | Forster, Martin David |
collection | PubMed |
description | Head and Neck Squamous Cell Carcinoma (HNSCC) is the 6th most common cancer globally and commonly presents with locally advanced disease, which has a recurrence rate of around 50% despite aggressive multi-modality treatment involving surgery, radiotherapy and chemotherapy or EGFR inhibition where appropriate. As understanding of the underlying cancer biology and the complex interactions within the tumor microenvironment improves, there is gathering interest in and evidence for the role of immunomodulating agents in the management of HNSCC. Immune checkpoint inhibitors, which aim to hinder the inhibitory interaction between programmed cell death protein 1 (PD-1) and its ligand PD-L1, have demonstrated durable improvements in patient outcomes in advanced / metastatic HNSCC, with both pembrolizumab and nivolumab being granted FDA approval in 2016. There are numerous ongoing clinical trials exploring the role of checkpoint inhibitors both as single agents and in combination, administered with established treatment modalities such as chemotherapy and radiotherapy, as well as alongside other novel immune modulators. These trials are not limited to advanced / metastatic HNSCC, but also to the neo-adjuvant or adjuvant settings. As studies complete and more results become available, the role immunotherapy agents will have within the treatment strategies for HNSCC may change, with increasing biomarker selection resulting in personalized therapy aiming to further improve patient outcomes. |
format | Online Article Text |
id | pubmed-6123367 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61233672018-09-12 Immune Checkpoint Inhibition in Head and Neck Cancer Forster, Martin David Devlin, Michael-John Front Oncol Immunology Head and Neck Squamous Cell Carcinoma (HNSCC) is the 6th most common cancer globally and commonly presents with locally advanced disease, which has a recurrence rate of around 50% despite aggressive multi-modality treatment involving surgery, radiotherapy and chemotherapy or EGFR inhibition where appropriate. As understanding of the underlying cancer biology and the complex interactions within the tumor microenvironment improves, there is gathering interest in and evidence for the role of immunomodulating agents in the management of HNSCC. Immune checkpoint inhibitors, which aim to hinder the inhibitory interaction between programmed cell death protein 1 (PD-1) and its ligand PD-L1, have demonstrated durable improvements in patient outcomes in advanced / metastatic HNSCC, with both pembrolizumab and nivolumab being granted FDA approval in 2016. There are numerous ongoing clinical trials exploring the role of checkpoint inhibitors both as single agents and in combination, administered with established treatment modalities such as chemotherapy and radiotherapy, as well as alongside other novel immune modulators. These trials are not limited to advanced / metastatic HNSCC, but also to the neo-adjuvant or adjuvant settings. As studies complete and more results become available, the role immunotherapy agents will have within the treatment strategies for HNSCC may change, with increasing biomarker selection resulting in personalized therapy aiming to further improve patient outcomes. Frontiers Media S.A. 2018-08-29 /pmc/articles/PMC6123367/ /pubmed/30211111 http://dx.doi.org/10.3389/fonc.2018.00310 Text en Copyright © 2018 Forster and Devlin. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Forster, Martin David Devlin, Michael-John Immune Checkpoint Inhibition in Head and Neck Cancer |
title | Immune Checkpoint Inhibition in Head and Neck Cancer |
title_full | Immune Checkpoint Inhibition in Head and Neck Cancer |
title_fullStr | Immune Checkpoint Inhibition in Head and Neck Cancer |
title_full_unstemmed | Immune Checkpoint Inhibition in Head and Neck Cancer |
title_short | Immune Checkpoint Inhibition in Head and Neck Cancer |
title_sort | immune checkpoint inhibition in head and neck cancer |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6123367/ https://www.ncbi.nlm.nih.gov/pubmed/30211111 http://dx.doi.org/10.3389/fonc.2018.00310 |
work_keys_str_mv | AT forstermartindavid immunecheckpointinhibitioninheadandneckcancer AT devlinmichaeljohn immunecheckpointinhibitioninheadandneckcancer |